文献速递药物不良反应与药物警戒

PV-RUCAM:支持常规药物警戒中药物性肝损伤因果评估的新型算法方法初步结果

Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
PubMed 文献 · Drug Saf · 2017-01-01

本研究开发了基于原始RUCAM七部分的PV-RUCAM算法评分,用于支持不完整药物警戒记录中疑似药物性肝损伤的因果评估。在药物临床试验报告和全球药物警戒数据库的数据集上评估,结果显示与标准方法中等一致,敏感性100%、特异性91%,与专家裁定Spearman相关系数R=0.93,评估者间一致性Kw=0.79。作者认为该工具可辅助非专家药物警戒人员,但常规使用前需前瞻性验证。

要点

  • PV-RUCAM在不完整报告中对排除DILI具有高敏感性(100%)和高阴性预测值(100%)。
  • 与专家裁定呈显著单调关联(R=0.93),两名评估者间一致性高(Kw=0.79)。
  • 阳性预测值仅25%,阳性结果需谨慎解读,常规使用前需前瞻性验证。

核心结论

  • 在制药公司药物警戒场景中,PV-RUCAM有潜力帮助非专家药物警戒人员评估不完整报告中的疑似DILI,但常规使用前需前瞻性验证。

研究设计与样本

  • 开发基于原始RUCAM七个部分的PV-RUCAM评分,设定支持或反对DILI因果关系的截断值。
  • 应用于两个从临床试验报告中随机提取的真实个例安全报告数据集,以及一个来自全球药物警戒数据库的电子健康记录数据集。
  • 将PV-RUCAM裁定性能与已验证的因果评估方法(原始RUCAM)和全局内省两种标准进行比较。

主要发现

  • PV-RUCAM与标准方法的一致性为中等。
  • 总体误差边际无假阴性,敏感性100%、特异性91%、阳性预测值25%、阴性预测值100%。
  • 专家裁定与PV-RUCAM输出之间Spearman秩相关系数R=0.93,呈统计学显著单调关联。
  • 两名PV-RUCAM评估者间一致性高,Kw=0.79。

临床怎么用

  • 在不完整药物警戒报告需评估疑似DILI时,PV-RUCAM可辅助非专家药物警戒专业人员进行评估。
  • 鉴于阳性预测值较低,PV-RUCAM阳性结果应结合临床综合判断,不宜单独作为确诊依据。

局限性

  • 研究结果为初步结果,常规使用前需进行前瞻性验证。
  • PV-RUCAM与标准方法的一致性仅为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Data incompleteness in pharmacovigilance (PV) health records limits the use of current causality assessment methods for drug-induced liver injury (DILI). In addition to the inherent complexity of this adverse event, identifying cases of high causal probability is difficult. OBJECTIVE: The aim was to evaluate the performance of an improved, algorithmic and standardised method called the Pharmacovigilance-Roussel Uclaf Causality Assessment Method (PV-RUCAM), to support assessment of suspected DILI. Performance was compared in different settings with regard to applicability and differentiation capacity. METHODS: A PV-RUCAM score was developed based on the seven sections contained in the original RUCAM. The score provides cut-off values for or against DILI causality, and was applied on two datasets of bona fide individual case safety reports (ICSRs) extracted randomly from clinical trial reports and a third dataset of electronic health records from a global PV database. The performance of PV-RUCAM adjudication was compared against two standards: a validated causality assessment method (original RUCAM) and global introspection. RESULTS: The findings showed moderate agreement against standards. The overall error margin of no false negatives was satisfactory, with 100% sensitivity, 91% specificity, a 25% positive predictive value and a 100% negative predictive value. The Spearman's rank correlation coefficient illustrated a statistically significant monotonic association between expert adjudication and PV-RUCAM outputs (R = 0.93). Finally, there was high inter-rater agreement (K w = 0.79) between two PV-RUCAM assessors. CONCLUSION: Within the PV setting of a pharmaceutical company, the PV-RUCAM has the potential to facilitate and improve the assessment done by non-expert PV professionals compared with other methods when incomplete reports must be evaluated for suspected DILI. Prospective validation of the algorithmic tool is necessary prior to implementation for routine use.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Scalfaro E, Streefkerk HJ, Merz M, et al. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM. Drug Saf. 2017. PMID: 28508325. doi:10.1007/s40264-017-0541-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。